Search

710 Result(s)
Sort by

Boehringer Ingelheim Office Hours Video 2023

Boehringer Ingelheim Office Hours Video 2023

Video providing an overview of Boehringer Ingelheim’s Office Hours program and how its mentoring and access to expertise can help early-stage companies advance their science.
Partnering Culture

Partnering Culture

BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.
About our Innovation Prize

About our Innovation Prize

Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Celebrating Innovation | Partnering

Celebrating Innovation | Partnering

BI’s Innovation Prize was established in Boston in 2015 to recognize the challenge and dedication of entrepreneurs in advancing new ideas & science.
Your Milestones Drive Ours

Your Milestones Drive Ours

Learn more about the experiences of living with nonsmall cell lung cancer and cholangiocarcinoma as well as caring for a loved one during a cancer journey.
See our Locations

See our Locations

We offer career development opportunities in over 170 locations across the world. Explore some of our featured locations.
Explore our company

Explore our company

Make your next career step at Boehringer Ingelheim. Explore our various fields to find out more about employment opportunities in your area of interest.
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC

Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC